NEWSLETTER
RSS
MOBILE
HELP
Molecular Insight Pharmaceuticals, Incorporated (MIPI)
SHARE
Email Confirmation
Dr. John W. Babich, Ph.D.
, Director/President/Founder/Chief Scientific Officer/Chairman of the Board/CEO
Industry: Healthcare
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME
Overview
News
People
Financials
Company Information
Dr. John W. Babich, Ph.D., Director/President/Founder/Chief Scientific Officer/Chairman of the Board/CEO
160 Second Street
Cambridge, MA 02142
US
Map it 
Overview
A biopharmaceutical company, which focuses on the research, development and commercialization of innovative molecular imaging pharmaceuticals and targeted radiotherapeutics designed to improve patient diagnosis, treatment and management.
News Feeds
-
Molecular Insight names 4 directors to board
AP
Sep 22 2008
Press Releases
-
Molecular Insight Pharmaceuticals, Inc. Adds Four Healthcare Industry Experts to Board of Directors Sep-22-2008, 08:30AM EDT
-
Molecular Insight Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference Sep-22-2008, 08:00AM EDT
-
Molecular Insight Pharmaceuticals, Inc. To Present at NewsMakers in the Biotech Industry Conference Aug-27-2008, 08:30AM EDT
-
Molecular Insight Pharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results Aug-13-2008, 08:30AM EDT
Employees
Number of Employees: 63
Revenue per Employee: $17,012
Top Executives
David S. Barlow, Director
Dr. James F. Kronauge, Ph.D., Vice President, Divisional
Brian Abeysekera, Ph.D., Vice President, Divisional
Joshua Hamermesh, Vice President, Divisional
Dr.John A. Barrett, Ph.D., Vice President, Divisional
Christine Huh, Vice President, Divisional
John E. McCray, COO
James Wachholz, Vice President, Divisional
Priscilla Harlan, Vice President, Divisional
Board of Directors
Dr. Scott Gottlieb, M.D., Director
Financials
Quarterly
Annual
| Income Statement | 08/2008 | 05/2008 | 04/2008 | 11/2007 |
|---|---|---|---|---|
| Sales | NA | -184.44 K. | -254.78 K. | -192.41 K. |
| Gross Operating Profit | 88 K. | 272.71 K. | 406.56 K. | 509.05 K. |
| Operating Income before D & A (EBITDA) | -16.34 Mil. | -14.95 Mil. | -19.15 Mil. | -13.44 Mil. |
| Total Income Before Interest Expenses (EBIT) | -15.22 Mil. | -13.86 Mil. | -18.46 Mil. | -13.15 Mil. |
| Total Net Income | -21.01 Mil. | -19.74 Mil. | -21.65 Mil. | -13.19 Mil. |
| Basic EPS, Total | -0.84 | -0.79 | -0.89 | -0.53 |
| Diluted EPS, Total | -0.84 | -0.79 | -0.89 | -0.53 |
| BALANCE STATEMENT | 08/2008 | 05/2008 | 04/2008 | 11/2007 |
|---|---|---|---|---|
| Cash and Equivalents | 28.89 Mil. | 52.19 Mil. | 62.12 Mil. | 14.67 Mil. |
| Total Assets | 125.59 Mil. | 126.42 Mil. | 121.01 Mil. | 39.9 Mil. |
| Total Liabilities | 11.86 Mil. | 11.24 Mil. | 15.01 Mil. | 12.95 Mil. |
| Total Capitalization | 133.6 Mil. | 149.14 Mil. | 161.69 Mil. | 30.06 Mil. |
| Cash Flow | 08/2008 | 05/2008 | 04/2008 | 11/2007 |
|---|---|---|---|---|
| Net Cash From Continuing Operations | NA | -16.94 Mil. | -44.87 Mil. | -31.48 Mil. |
| Net Cash From Investing Activities | NA | 6.99 Mil. | -105.4 Mil. | -25.49 Mil. |
| Net Cash From Financing Activities | NA | 38 K. | 203.47 Mil. | 62.72 Mil. |
| Net Change in Cash & Cash Equivalents | NA | -9.92 Mil. | 53.2 Mil. | 5.76 Mil. |
| Income Statement | 2008 | 2007 | 2007 |
|---|---|---|---|
| Sales | -721.89 K. | -307.03 K. | -139.28 K. |
| Gross Operating Profit | 1.45 Mil. | 632.1 K. | 1.37 Mil. |
| Operating Income before D & A (EBITDA) | -56.95 Mil. | -26.21 Mil. | -18.51 Mil. |
| Total Income Before Interest Expenses (EBIT) | -55.1 Mil. | -26.05 Mil. | -18.16 Mil. |
| Total Net Income | -59.83 Mil. | -27.27 Mil. | -18.3 Mil. |
| Basic EPS, Total | -2.65 | -7.18 | -5.3 |
| Diluted EPS, Total | -2.65 | -7.18 | -5.3 |
| BALANCE STATEMENT | 2008 | 2007 | 2007 |
|---|---|---|---|
| Cash and Equivalents | 62.12 Mil. | 8.92 Mil. | 5.81 Mil. |
| Total Assets | 121.01 Mil. | 10.61 Mil. | 19.1 Mil. |
| Total Liabilities | 15.01 Mil. | 10.01 Mil. | 6.13 Mil. |
| Total Capitalization | 161.69 Mil. | -45.19 Mil. | -31.77 Mil. |
| Cash Flow | 2008 | 2007 | 2007 |
|---|---|---|---|
| Net Cash From Continuing Operations | -44.87 Mil. | -22.09 Mil. | -14.21 Mil. |
| Net Cash From Investing Activities | -105.4 Mil. | 11.86 Mil. | -12.8 Mil. |
| Net Cash From Financing Activities | 203.47 Mil. | 13.34 Mil. | 31.97 Mil. |
| Net Change in Cash & Cash Equivalents | 53.2 Mil. | 3.11 Mil. | 4.96 Mil. |
Related Companies by Market Cap
Company Name
Price
Change
Market Cap
215.89 Mil.
221.01 Mil.
212.12 Mil.
211.45 Mil.
Company Profile Change Request
The data provided in our company profiles comes from third party information providers.- To request a change please click here
Also in Portfolio.com
Most Read
Most Emailed
Recently Commented
TOP 5
(Daily)
A smart take on the top stories shaping the business world.
Executives & Careers
(Tuesdays)
A weekly guide to the personalities and ideas that are transforming the business world.
Inside Portfolio.com
(Wednesdays)
Our roundup of the week's best from Portfolio.com.
Culture & Lifestyle
(Fridays)
A weekly guide to the best ways to spend your time - and money.
In This Issue
(Monthly)
Be the first to know when the latest issue of Condé Nast Portfolio magazine is online.
RSS Most Read
Mobile